|
Gene: LRRIQ1 |
Gene summary for LRRIQ1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | LRRIQ1 | Gene ID | 84125 |
Gene name | leucine rich repeats and IQ motif containing 1 | |
Gene Alias | LRRIQ1 | |
Cytomap | 12q21.31 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | A0A140VJN5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84125 | LRRIQ1 | RNA-P6T1-P6T1-1 | Human | Lung | MIAC | 9.93e-08 | 1.04e+00 | -0.0238 |
84125 | LRRIQ1 | RNA-P6T1-P6T1-2 | Human | Lung | MIAC | 3.39e-12 | 1.21e+00 | -0.0186 |
84125 | LRRIQ1 | RNA-P6T1-P6T1-3 | Human | Lung | MIAC | 2.21e-10 | 1.22e+00 | -0.0296 |
84125 | LRRIQ1 | RNA-P6T1-P6T1-4 | Human | Lung | MIAC | 2.95e-10 | 1.04e+00 | -0.0263 |
84125 | LRRIQ1 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.74e-03 | 3.98e-01 | -0.0822 |
84125 | LRRIQ1 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 4.67e-04 | 3.88e-01 | -0.0809 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Lung | AAH: Atypical adenomatous hyperplasia | |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRRIQ1 | SNV | Missense_Mutation | c.4720G>A | p.Asp1574Asn | p.D1574N | Q96JM4 | protein_coding | deleterious(0.03) | possibly_damaging(0.755) | TCGA-97-A4M5-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
LRRIQ1 | SNV | Missense_Mutation | novel | c.3811G>C | p.Val1271Leu | p.V1271L | Q96JM4 | protein_coding | tolerated(0.65) | benign(0.014) | TCGA-J2-A4AD-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
LRRIQ1 | SNV | Missense_Mutation | novel | c.2578N>G | p.Leu860Val | p.L860V | Q96JM4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-L9-A444-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LRRIQ1 | SNV | Missense_Mutation | novel | c.4927N>A | p.Glu1643Lys | p.E1643K | Q96JM4 | protein_coding | deleterious(0.02) | probably_damaging(0.965) | TCGA-L9-A743-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | taxotere | CR |
LRRIQ1 | SNV | Missense_Mutation | novel | c.1206N>C | p.Lys402Asn | p.K402N | Q96JM4 | protein_coding | tolerated(0.05) | benign(0.029) | TCGA-MN-A4N4-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
LRRIQ1 | SNV | Missense_Mutation | c.1958N>A | p.Ser653Asn | p.S653N | Q96JM4 | protein_coding | tolerated(0.36) | benign(0.153) | TCGA-MN-A4N4-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
LRRIQ1 | SNV | Missense_Mutation | c.3154G>T | p.Ala1052Ser | p.A1052S | Q96JM4 | protein_coding | tolerated(0.51) | benign(0.038) | TCGA-21-1070-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
LRRIQ1 | SNV | Missense_Mutation | c.2536G>A | p.Asp846Asn | p.D846N | Q96JM4 | protein_coding | tolerated(0.31) | possibly_damaging(0.72) | TCGA-22-4613-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LRRIQ1 | SNV | Missense_Mutation | novel | c.1299N>T | p.Lys433Asn | p.K433N | Q96JM4 | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-22-A5C4-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LRRIQ1 | SNV | Missense_Mutation | novel | c.4124N>G | p.Lys1375Arg | p.K1375R | Q96JM4 | protein_coding | tolerated(0.26) | benign(0.009) | TCGA-33-AASI-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |